Sign Out
Pregnancy: There are limited data from the use of linagliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
As a precautionary measure, it is preferable to avoid the use of Linagliptin (Trajenta) during pregnancy.
Lactation: Available pharmacodynamic/toxicological data in animals have shown excretion of linagliptin/metabolites in milk.
It is not known whether this drug is excreted in human milk. Caution should be exercised when Linagliptin (Trajenta) is administered to a nursing woman.
Fertility: No studies on the effect on human fertility have been conducted for Linagliptin (Trajenta). No adverse effects on fertility were observed in animals up to the highest dose of 240 mg/kg/day (approximately 943 times human exposure based on AUC comparisons).
